These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
[X]
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
[ ]
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Delaware
|
94-3025618
|
|
(State or other jurisdiction of incorporation or organization)
|
(IRS Employer Identification Number)
|
|
Title of each class
|
Name of each exchange on which registered
|
|
Common Stock
|
The NASDAQ Global Select Market
|
|
Large Accelerated Filer
|
___
|
Accelerated Filer
|
X
|
|
Non Accelerated Filer
|
___
|
Smaller Reporting Company
|
___
|
|
Emerging Growth Company
|
___
|
|
|
|
|
|
|
|
Page
|
|
|
|
|
||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
February 24, 2019
|
|
May 27, 2018
|
||||
|
|
(unaudited)
|
|
|
||||
|
ASSETS
|
|
|
|
||||
|
Current Assets:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
1,722
|
|
|
$
|
2,899
|
|
|
Accounts receivable, less allowance for doubtful accounts
|
60,390
|
|
|
53,877
|
|
||
|
Inventories
|
44,227
|
|
|
31,819
|
|
||
|
Prepaid expenses and other current assets
|
7,994
|
|
|
7,958
|
|
||
|
Other current assets, discontinued operations
|
—
|
|
|
510
|
|
||
|
Total Current Assets
|
114,333
|
|
|
97,063
|
|
||
|
|
|
|
|
||||
|
Investment in non-public company, fair value
|
68,100
|
|
|
66,500
|
|
||
|
Property and equipment, net
|
191,892
|
|
|
159,624
|
|
||
|
Goodwill
|
75,739
|
|
|
54,510
|
|
||
|
Trademarks/tradenames, net
|
31,928
|
|
|
16,028
|
|
||
|
Customer relationships, net
|
15,821
|
|
|
5,814
|
|
||
|
Other assets
|
3,770
|
|
|
5,164
|
|
||
|
Total Assets
|
$
|
501,583
|
|
|
$
|
404,703
|
|
|
|
|
|
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
||||
|
Current Liabilities:
|
|
|
|
||||
|
Accounts payable
|
$
|
46,431
|
|
|
$
|
34,668
|
|
|
Accrued compensation
|
7,029
|
|
|
9,978
|
|
||
|
Other accrued liabilities
|
10,406
|
|
|
8,706
|
|
||
|
Deferred revenue
|
1,286
|
|
|
2,625
|
|
||
|
Line of credit
|
44,000
|
|
|
27,000
|
|
||
|
Current portion of long-term debt
|
9,791
|
|
|
4,940
|
|
||
|
Other current liabilities, discontinued operations
|
—
|
|
|
458
|
|
||
|
Total Current Liabilities
|
118,943
|
|
|
88,375
|
|
||
|
|
|
|
|
||||
|
Long-term debt, net
|
89,637
|
|
|
37,360
|
|
||
|
Capital lease obligation, less current portion
|
3,562
|
|
|
3,641
|
|
||
|
Deferred taxes, net
|
17,395
|
|
|
17,485
|
|
||
|
Other non-current liabilities
|
1,982
|
|
|
5,280
|
|
||
|
Total Liabilities
|
231,519
|
|
|
152,141
|
|
||
|
|
|
|
|
||||
|
Stockholders’ Equity:
|
|
|
|
||||
|
Common stock, $0.001 par value; 50,000 shares authorized; 29,006 and 27,702 shares issued and outstanding at February 24, 2019 and May 27, 2018, respectively
|
29
|
|
|
28
|
|
||
|
Additional paid-in capital
|
159,524
|
|
|
142,087
|
|
||
|
Retained earnings
|
109,971
|
|
|
109,299
|
|
||
|
Accumulated other comprehensive income
|
540
|
|
|
1,148
|
|
||
|
Total Stockholders’ Equity
|
270,064
|
|
|
252,562
|
|
||
|
Total Liabilities and Stockholders’ Equity
|
$
|
501,583
|
|
|
$
|
404,703
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
February 24, 2019
|
|
February 25, 2018
|
|
February 24, 2019
|
|
February 25, 2018
|
||||||||
|
Product sales
|
$
|
155,687
|
|
|
$
|
144,909
|
|
|
$
|
405,267
|
|
|
$
|
383,151
|
|
|
Cost of product sales
|
134,470
|
|
|
125,103
|
|
|
351,120
|
|
|
329,622
|
|
||||
|
Gross profit
|
21,217
|
|
|
19,806
|
|
|
54,147
|
|
|
53,529
|
|
||||
|
Operating costs and expenses:
|
|
|
|
|
|
|
|
||||||||
|
Research and development
|
2,741
|
|
|
3,113
|
|
|
8,107
|
|
|
9,204
|
|
||||
|
Selling, general and administrative
|
15,843
|
|
|
13,208
|
|
|
44,460
|
|
|
38,810
|
|
||||
|
Total operating costs and expenses
|
18,584
|
|
|
16,321
|
|
|
52,567
|
|
|
48,014
|
|
||||
|
Operating income
|
2,633
|
|
|
3,485
|
|
|
1,580
|
|
|
5,515
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Dividend income
|
413
|
|
|
413
|
|
|
1,238
|
|
|
1,238
|
|
||||
|
Interest income
|
34
|
|
|
87
|
|
|
113
|
|
|
160
|
|
||||
|
Interest expense
|
(1,771
|
)
|
|
(531
|
)
|
|
(3,275
|
)
|
|
(1,415
|
)
|
||||
|
Other income
|
—
|
|
|
—
|
|
|
1,600
|
|
|
2,200
|
|
||||
|
Net income from continuing operations before tax
|
1,309
|
|
|
3,454
|
|
|
1,256
|
|
|
7,698
|
|
||||
|
Income tax (expense) benefit
|
(242
|
)
|
|
12,827
|
|
|
(584
|
)
|
|
11,352
|
|
||||
|
Net income from continuing operations
|
$
|
1,067
|
|
|
$
|
16,281
|
|
|
$
|
672
|
|
|
$
|
19,050
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Discontinued operations:
|
|
|
|
|
|
|
|
||||||||
|
Loss from discontinued operations
|
$
|
—
|
|
|
$
|
(277
|
)
|
|
$
|
—
|
|
|
$
|
(339
|
)
|
|
Income tax benefit
|
—
|
|
|
82
|
|
|
—
|
|
|
100
|
|
||||
|
Loss from discontinued operations, net of tax
|
—
|
|
|
(195
|
)
|
|
—
|
|
|
(239
|
)
|
||||
|
Consolidated net income
|
1,067
|
|
|
16,086
|
|
|
672
|
|
|
18,811
|
|
||||
|
Non-controlling interest benefit (expense)
|
—
|
|
|
2
|
|
|
—
|
|
|
(90
|
)
|
||||
|
Net income applicable to common stockholders
|
$
|
1,067
|
|
|
$
|
16,088
|
|
|
$
|
672
|
|
|
$
|
18,721
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Basic net income per share:
|
|
|
|
|
|
|
|
||||||||
|
Income from continuing operations
|
$
|
0.04
|
|
|
$
|
0.59
|
|
|
$
|
0.02
|
|
|
$
|
0.69
|
|
|
Loss from discontinued operations
|
—
|
|
|
(0.01
|
)
|
|
—
|
|
|
(0.01
|
)
|
||||
|
Total basic net income per share
|
$
|
0.04
|
|
|
$
|
0.58
|
|
|
$
|
0.02
|
|
|
$
|
0.68
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Diluted net income per share
|
|
|
|
|
|
|
|
||||||||
|
Income from continuing operations
|
$
|
0.04
|
|
|
$
|
0.58
|
|
|
$
|
0.02
|
|
|
$
|
0.68
|
|
|
Loss from discontinued operations
|
—
|
|
|
(0.01
|
)
|
|
—
|
|
|
(0.01
|
)
|
||||
|
Total diluted net income per share
|
$
|
0.04
|
|
|
$
|
0.57
|
|
|
$
|
0.02
|
|
|
$
|
0.67
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Shares used in per share computation
|
|
|
|
|
|
|
|
||||||||
|
Basic
|
28,919
|
|
|
27,547
|
|
|
28,140
|
|
|
27,524
|
|
||||
|
Diluted
|
29,151
|
|
|
27,918
|
|
|
28,399
|
|
|
27,884
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Other comprehensive (loss) income, net of tax:
|
|
|
|
|
|
|
|
||||||||
|
Net unrealized (losses) gains on interest rate swaps (net of tax effect of $215, $(210), $190, and $(552))
|
$
|
(595
|
)
|
|
$
|
347
|
|
|
$
|
(608
|
)
|
|
$
|
483
|
|
|
Other comprehensive (loss) income, net of tax
|
(595
|
)
|
|
347
|
|
|
(608
|
)
|
|
483
|
|
||||
|
Total comprehensive income
|
$
|
472
|
|
|
$
|
16,435
|
|
|
$
|
64
|
|
|
$
|
19,204
|
|
|
|
|
|
|
|
Additional
Paid-in
Capital
|
|
Retained
Earnings
|
|
Accumulated
Other
Comprehensive
Income
|
|
Total
Stockholders’
Equity
|
||||||
|
|
Common Stock
|
|
|
|
|
||||||||||||
|
|
Shares
|
|
Amount
|
|
|
|
|
||||||||||
|
Balance at May 27, 2018
|
27,702
|
|
|
28
|
|
|
142,087
|
|
|
109,299
|
|
|
1,148
|
|
|
252,562
|
|
|
Issuance of stock under stock plans
|
47
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Taxes paid by Company for employee stock plans
|
—
|
|
|
—
|
|
|
(10
|
)
|
|
—
|
|
|
—
|
|
|
(10
|
)
|
|
Stock-based compensation
|
—
|
|
|
—
|
|
|
728
|
|
|
—
|
|
|
—
|
|
|
728
|
|
|
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
190
|
|
|
—
|
|
|
190
|
|
|
Other comprehensive loss, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(89
|
)
|
|
(89
|
)
|
|
Balance at August 26, 2018
|
27,749
|
|
|
28
|
|
|
142,805
|
|
|
109,489
|
|
|
1,059
|
|
|
253,381
|
|
|
Issuance of stock under stock plans
|
36
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Taxes paid by Company for employee stock plans
|
—
|
|
|
—
|
|
|
(237
|
)
|
|
—
|
|
|
—
|
|
|
(237
|
)
|
|
Stock-based compensation
|
—
|
|
|
—
|
|
|
938
|
|
|
—
|
|
|
—
|
|
|
938
|
|
|
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
(585
|
)
|
|
—
|
|
|
(585
|
)
|
|
Other comprehensive income, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
|
|
|
76
|
|
|
76
|
|
|
Balance at November 25, 2018
|
27,785
|
|
|
28
|
|
|
143,506
|
|
|
108,904
|
|
|
1,135
|
|
|
253,573
|
|
|
Issuance of stock under stock plans
|
18
|
|
|
—
|
|
|
230
|
|
|
—
|
|
|
—
|
|
|
230
|
|
|
Issuance of common stock in connection with the Yucatan Foods acquisition
|
1,203
|
|
|
1
|
|
|
15,067
|
|
|
—
|
|
|
—
|
|
|
15,068
|
|
|
Taxes paid by Company for employee stock plans
|
—
|
|
|
—
|
|
|
(95
|
)
|
|
—
|
|
|
—
|
|
|
(95
|
)
|
|
Stock-based compensation
|
—
|
|
|
—
|
|
|
816
|
|
|
—
|
|
|
—
|
|
|
816
|
|
|
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
1,067
|
|
|
—
|
|
|
1,067
|
|
|
Other comprehensive loss, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(595
|
)
|
|
(595
|
)
|
|
Balance at February 24, 2019
|
29,006
|
|
|
29
|
|
|
159,524
|
|
|
109,971
|
|
|
540
|
|
|
270,064
|
|
|
|
Nine Months Ended
|
||||||
|
|
February 24, 2019
|
|
February 25, 2018
|
||||
|
Cash flows from operating activities:
|
|
|
|
||||
|
Consolidated net income
|
$
|
672
|
|
|
$
|
18,811
|
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
||||
|
Depreciation and amortization
|
10,506
|
|
|
9,076
|
|
||
|
Stock-based compensation expense
|
2,482
|
|
|
3,212
|
|
||
|
Deferred taxes
|
540
|
|
|
(9,055
|
)
|
||
|
Change in investment in non-public company, fair value
|
(1,600
|
)
|
|
(2,200
|
)
|
||
|
Change in contingent consideration liability
|
(3,500
|
)
|
|
—
|
|
||
|
Net (gain) loss on disposal of property and equipment
|
(24
|
)
|
|
93
|
|
||
|
Changes in current assets and current liabilities:
|
|
|
|
||||
|
Accounts receivable, net
|
315
|
|
|
(3,355
|
)
|
||
|
Inventories
|
(1,024
|
)
|
|
(3,459
|
)
|
||
|
Prepaid expenses and other current assets
|
1,066
|
|
|
(3,876
|
)
|
||
|
Accounts payable
|
11,912
|
|
|
11,575
|
|
||
|
Accrued compensation
|
(3,061
|
)
|
|
(1,548
|
)
|
||
|
Other accrued liabilities
|
755
|
|
|
(449
|
)
|
||
|
Deferred revenue
|
(1,590
|
)
|
|
1,475
|
|
||
|
Net cash provided by operating activities
|
17,449
|
|
|
20,300
|
|
||
|
|
|
|
|
||||
|
Cash flows from investing activities:
|
|
|
|
||||
|
Purchases of property and equipment
|
(33,144
|
)
|
|
(20,735
|
)
|
||
|
Acquisition of Yucatan Foods (Note 2), net of cash acquired
|
(59,872
|
)
|
|
—
|
|
||
|
Issuance of note receivable
|
—
|
|
|
(2,099
|
)
|
||
|
Proceeds from collections of notes receivable
|
404
|
|
|
—
|
|
||
|
Proceeds from sales of fixed assets
|
239
|
|
|
88
|
|
||
|
Net cash used in investing activities
|
(92,373
|
)
|
|
(22,746
|
)
|
||
|
|
|
|
|
||||
|
Cash flows from financing activities:
|
|
|
|
||||
|
Proceeds from sale of common stock
|
230
|
|
|
1
|
|
||
|
Taxes paid by Company for employee stock plans
|
(342
|
)
|
|
(394
|
)
|
||
|
Payments on long-term debt
|
(2,564
|
)
|
|
(3,805
|
)
|
||
|
Proceeds from lines of credit
|
34,000
|
|
|
18,000
|
|
||
|
Proceeds from debt
|
60,000
|
|
|
—
|
|
||
|
Payments on lines of credit
|
(17,000
|
)
|
|
(9,000
|
)
|
||
|
Payments for debt issuance costs
|
(509
|
)
|
|
—
|
|
||
|
Payments to non-controlling interest
|
—
|
|
|
(115
|
)
|
||
|
Net cash provided by financing activities
|
73,815
|
|
|
4,687
|
|
||
|
Net (decrease) increase in cash, cash equivalents and restricted cash (1)
|
(1,109
|
)
|
|
2,241
|
|
||
|
Cash, cash equivalents and restricted cash, beginning of period (1)
|
3,216
|
|
|
5,734
|
|
||
|
Cash, cash equivalents and restricted cash, end of period (1)
|
$
|
2,107
|
|
|
$
|
7,975
|
|
|
|
|
|
|
||||
|
Supplemental disclosure of non-cash investing and financing activities:
|
|
|
|
||||
|
Purchases of property and equipment on trade vendor credit
|
$
|
3,035
|
|
|
$
|
2,178
|
|
|
(1)
|
As a result of adopting ASU 2016-18, cash and cash equivalents at the beginning-of-period and end-of-period total amounts have been adjusted.
|
|
|
February 24,
2019 |
|
May 27,
2018 |
|
February 25,
2018 |
|
May 29,
2017 |
||||||||
|
Cash and cash equivalents
|
$
|
1,722
|
|
|
$
|
2,899
|
|
|
$
|
7,660
|
|
|
$
|
5,998
|
|
|
Restricted cash
|
385
|
|
|
325
|
|
|
325
|
|
|
325
|
|
||||
|
Cash, discontinued operations
|
—
|
|
|
(8
|
)
|
|
(10
|
)
|
|
(589
|
)
|
||||
|
Cash, cash equivalents and restricted cash
|
$
|
2,107
|
|
|
$
|
3,216
|
|
|
$
|
7,975
|
|
|
$
|
5,734
|
|
|
|
February 24,
2019 |
|
May 27,
2018 |
||||
|
Raw materials
|
$
|
18,821
|
|
|
$
|
15,286
|
|
|
Work in progress
|
3,385
|
|
|
3,672
|
|
||
|
Finished goods
|
22,021
|
|
|
12,861
|
|
||
|
Total
|
$
|
44,227
|
|
|
$
|
31,819
|
|
|
|
|
|
|
||||
|
|
AOCI
|
||
|
Accumulated OCI, net, as of May 27, 2018
|
$
|
1,148
|
|
|
Unrealized losses on interest rate swap contracts, net of tax effect
|
(608
|
)
|
|
|
Amounts reclassified from OCI
|
—
|
|
|
|
Accumulated OCI, net, as of February 24, 2019
|
$
|
540
|
|
|
|
At February 24,
2019 |
|
At May 27,
2018 |
|
Cost of debt
|
5.1% to 5.5%
|
|
4.7% to 5.2%
|
|
Market price of risk adjustment
|
14%
|
|
20%
|
|
EBITDA volatility
|
28%
|
|
25%
|
|
|
Impact on value of
Contingent consideration liability as of February 24, 2019 |
||
|
10% increase in EBITDA forecast
|
$
|
100
|
|
|
|
At February 24,
2019 |
|
At May 27,
2018 |
|
Revenue growth rates
|
6%
|
|
6%
|
|
Expense growth rates
|
6%
|
|
6%
|
|
Income tax rates
|
15%
|
|
15%
|
|
Discount rates
|
12%
|
|
12%
|
|
|
Impact on value of
investment in Windset as of February 24, 2019 |
||
|
10% increase in revenue growth rates
|
$
|
10,000
|
|
|
10% increase in expense growth rates
|
$
|
(9,300
|
)
|
|
10% increase in income tax rates
|
$
|
(500
|
)
|
|
10% increase in discount rates
|
$
|
(3,700
|
)
|
|
|
Fair Value at February 24, 2019
|
|
Fair Value at May 27, 2018
|
||||||||||||||||||||
|
Assets:
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
||||||||||||
|
Interest rate swap contracts
|
$
|
—
|
|
|
$
|
992
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,529
|
|
|
$
|
—
|
|
|
Investment in non-public company
|
—
|
|
|
—
|
|
|
68,100
|
|
|
—
|
|
|
—
|
|
|
66,500
|
|
||||||
|
Total assets
|
$
|
—
|
|
|
$
|
992
|
|
|
$
|
68,100
|
|
|
$
|
—
|
|
|
$
|
1,529
|
|
|
$
|
66,500
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Interest rate swap contracts
|
—
|
|
|
259
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Contingent consideration liability
|
—
|
|
|
—
|
|
|
500
|
|
|
—
|
|
|
—
|
|
|
4,000
|
|
||||||
|
Total liabilities
|
$
|
—
|
|
|
$
|
259
|
|
|
$
|
500
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
4,000
|
|
|
|
Windset Investment
|
|
Contingent Consideration Liability
|
||||
|
Balance as of May 27, 2018
|
$
|
66,500
|
|
|
$
|
4,000
|
|
|
Fair value change
|
1,600
|
|
|
(3,500
|
)
|
||
|
Balance as of February 24, 2019
|
$
|
68,100
|
|
|
$
|
500
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
Curation Foods:
|
February 24,
2019 |
|
February 25,
2018 |
|
February 24,
2019 |
|
February 25,
2018 |
||||||||
|
Salads
|
$
|
49,387
|
|
|
$
|
48,492
|
|
|
$
|
140,417
|
|
|
$
|
135,118
|
|
|
Core vegetables
|
68,070
|
|
|
72,256
|
|
|
195,203
|
|
|
193,805
|
|
||||
|
Emerging brands
|
14,527
|
|
|
1,202
|
|
|
17,882
|
|
|
4,992
|
|
||||
|
Total
|
$
|
131,984
|
|
|
$
|
121,950
|
|
|
$
|
353,502
|
|
|
$
|
333,915
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
Lifecore:
|
February 24,
2019 |
|
February 25,
2018 |
|
February 24,
2019 |
|
February 25,
2018 |
||||||||
|
Aseptic
|
$
|
7,432
|
|
|
$
|
7,600
|
|
|
$
|
21,326
|
|
|
$
|
22,218
|
|
|
Fermentation
|
11,451
|
|
|
12,175
|
|
|
16,436
|
|
|
17,830
|
|
||||
|
Development services
|
4,820
|
|
|
3,184
|
|
|
14,003
|
|
|
9,188
|
|
||||
|
Total
|
$
|
23,703
|
|
|
$
|
22,959
|
|
|
$
|
51,765
|
|
|
$
|
49,236
|
|
|
•
|
Evaluating the nature of its real and personal property and other arrangements that may meet the definition of a lease; and
|
|
(in thousands)
|
|
||
|
Cash consideration
|
$
|
59,898
|
|
|
Stock consideration
|
15,068
|
|
|
|
|
$
|
74,966
|
|
|
(in thousands)
|
|
||
|
Cash and cash equivalents
|
$
|
26
|
|
|
Accounts receivable
|
6,310
|
|
|
|
Inventories
|
11,384
|
|
|
|
Prepaid expenses and other current assets
|
869
|
|
|
|
Deferred tax assets
|
443
|
|
|
|
Other assets
|
102
|
|
|
|
Property and equipment
|
14,083
|
|
|
|
Trademarks/tradenames
|
15,900
|
|
|
|
Customer relationships
|
11,000
|
|
|
|
Accounts payable
|
(4,507
|
)
|
|
|
Other accrued liabilities
|
(1,873
|
)
|
|
|
Net identifiable assets acquired
|
53,737
|
|
|
|
Goodwill
|
21,229
|
|
|
|
Total fair value purchase consideration
|
$
|
74,966
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
February 24, 2019
|
|
February 25, 2018
|
|
February 24, 2019
|
|
February 25, 2018
|
||||||||
|
Options
|
$
|
245
|
|
|
$
|
380
|
|
|
$
|
689
|
|
|
$
|
1,057
|
|
|
RSUs
|
571
|
|
|
767
|
|
|
1,793
|
|
|
2,155
|
|
||||
|
Total stock-based compensation
|
$
|
816
|
|
|
$
|
1,147
|
|
|
$
|
2,482
|
|
|
$
|
3,212
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
February 24, 2019
|
|
February 25, 2018
|
|
February 24, 2019
|
|
February 25, 2018
|
||||||||
|
Cost of sales
|
$
|
116
|
|
|
$
|
137
|
|
|
$
|
334
|
|
|
$
|
398
|
|
|
Research and development
|
29
|
|
|
41
|
|
|
84
|
|
|
82
|
|
||||
|
Selling, general and administrative
|
671
|
|
|
969
|
|
|
2,064
|
|
|
2,732
|
|
||||
|
Total stock-based compensation
|
$
|
816
|
|
|
$
|
1,147
|
|
|
$
|
2,482
|
|
|
$
|
3,212
|
|
|
(in thousands, except per share amounts)
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
February 24,
2019 |
|
February 25,
2018 |
|
February 24,
2019 |
|
February 25,
2018 |
||||||||
|
Numerator:
|
|
|
|
|
|
|
|
||||||||
|
Net income applicable to Common Stockholders
|
$
|
1,067
|
|
|
$
|
16,088
|
|
|
$
|
672
|
|
|
$
|
18,721
|
|
|
Denominator:
|
|
|
|
|
|
|
|
||||||||
|
Weighted average shares for basic net income per share
|
28,919
|
|
|
27,547
|
|
|
28,140
|
|
|
27,524
|
|
||||
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
||||||||
|
Stock options and restricted stock units
|
232
|
|
|
371
|
|
|
259
|
|
|
360
|
|
||||
|
Weighted average shares for diluted net income per share
|
29,151
|
|
|
27,918
|
|
|
28,399
|
|
|
27,884
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Diluted net income per share
|
$
|
0.04
|
|
|
$
|
0.57
|
|
|
$
|
0.02
|
|
|
$
|
0.67
|
|
|
|
February 24, 2019
|
|
May 27, 2018
|
||||
|
Term loan
|
$
|
100,000
|
|
|
$
|
42,500
|
|
|
Total principal amount of long-term debt
|
100,000
|
|
|
42,500
|
|
||
|
Less: unamortized debt issuance costs
|
(572
|
)
|
|
(200
|
)
|
||
|
Total long-term debt, net of unamortized debt issuance costs
|
99,428
|
|
|
42,300
|
|
||
|
Less: current portion of long-term debt, net
|
(9,791
|
)
|
|
(4,940
|
)
|
||
|
Long-term debt, net
|
$
|
89,637
|
|
|
$
|
37,360
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
February 24, 2019
|
|
February 25, 2018
|
|
February 24, 2019
|
|
February 25, 2018
|
||||||||
|
Canada
|
$
|
24.1
|
|
|
$
|
20.3
|
|
|
$
|
64.3
|
|
|
$
|
55.9
|
|
|
Belgium
|
$
|
9.9
|
|
|
$
|
11.5
|
|
|
$
|
12.4
|
|
|
$
|
14.3
|
|
|
Ireland
|
$
|
1.4
|
|
|
$
|
—
|
|
|
$
|
3.7
|
|
|
$
|
3.2
|
|
|
Denmark
|
$
|
0.1
|
|
|
$
|
—
|
|
|
$
|
0.3
|
|
|
$
|
—
|
|
|
Switzerland
|
$
|
0.2
|
|
|
$
|
—
|
|
|
$
|
0.8
|
|
|
$
|
—
|
|
|
Mexico
|
$
|
0.4
|
|
|
$
|
0.2
|
|
|
$
|
0.5
|
|
|
$
|
0.2
|
|
|
All Other Countries
|
$
|
0.1
|
|
|
$
|
1.5
|
|
|
$
|
1.3
|
|
|
$
|
2.0
|
|
|
|
Curation Foods
(1)
|
|
Lifecore
|
|
Other
|
|
Total
|
||||||||
|
Three Months Ended February 24, 2019
|
|
|
|
|
|
|
|
||||||||
|
Net sales
|
$
|
131,984
|
|
|
$
|
23,703
|
|
|
$
|
—
|
|
|
$
|
155,687
|
|
|
International sales
|
$
|
24,172
|
|
|
$
|
12,029
|
|
|
$
|
—
|
|
|
$
|
36,201
|
|
|
Gross profit
|
$
|
9,641
|
|
|
$
|
11,576
|
|
|
$
|
—
|
|
|
$
|
21,217
|
|
|
Net income (loss) from continuing operations
|
$
|
(6,817
|
)
|
|
$
|
5,836
|
|
|
$
|
2,048
|
|
|
$
|
1,067
|
|
|
Depreciation and amortization
|
$
|
2,875
|
|
|
$
|
1,028
|
|
|
$
|
145
|
|
|
$
|
4,048
|
|
|
Dividend income
|
$
|
413
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
413
|
|
|
Interest income
|
$
|
26
|
|
|
$
|
—
|
|
|
$
|
8
|
|
|
$
|
34
|
|
|
Interest expense, net
(2)
|
$
|
1,164
|
|
|
$
|
—
|
|
|
$
|
607
|
|
|
$
|
1,771
|
|
|
Income tax (benefit) expense
|
$
|
(829
|
)
|
|
$
|
1,946
|
|
|
$
|
(875
|
)
|
|
$
|
242
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Nine Months Ended February 24, 2019
|
|
|
|
|
|
|
|
||||||||
|
Net sales
|
$
|
353,502
|
|
|
$
|
51,765
|
|
|
$
|
—
|
|
|
$
|
405,267
|
|
|
International sales
|
$
|
64,732
|
|
|
$
|
18,587
|
|
|
$
|
—
|
|
|
$
|
83,319
|
|
|
Gross profit
|
$
|
33,926
|
|
|
$
|
20,221
|
|
|
$
|
—
|
|
|
$
|
54,147
|
|
|
Net income (loss) from continuing operations
|
$
|
(5,466
|
)
|
|
$
|
6,586
|
|
|
$
|
(448
|
)
|
|
$
|
672
|
|
|
Depreciation and amortization
|
$
|
7,111
|
|
|
$
|
2,982
|
|
|
$
|
413
|
|
|
$
|
10,506
|
|
|
Dividend income
|
$
|
1,238
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,238
|
|
|
Interest income
|
$
|
87
|
|
|
$
|
—
|
|
|
$
|
26
|
|
|
$
|
113
|
|
|
Interest expense, net
(2)
|
$
|
2,027
|
|
|
$
|
—
|
|
|
$
|
1,248
|
|
|
$
|
3,275
|
|
|
Income tax (benefit) expense
|
$
|
(217
|
)
|
|
$
|
2,196
|
|
|
$
|
(1,395
|
)
|
|
$
|
584
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended February 25, 2018
|
|
|
|
|
|
|
|
|
|||||||
|
Net sales
|
$
|
121,950
|
|
|
$
|
22,959
|
|
|
$
|
—
|
|
|
$
|
144,909
|
|
|
International sales
|
$
|
20,336
|
|
|
$
|
13,156
|
|
|
$
|
—
|
|
|
$
|
33,492
|
|
|
Gross profit
|
$
|
8,197
|
|
|
$
|
11,609
|
|
|
$
|
—
|
|
|
$
|
19,806
|
|
|
Net income (loss) from continuing operations
|
$
|
(2,801
|
)
|
|
$
|
6,175
|
|
|
$
|
12,907
|
|
|
$
|
16,281
|
|
|
Depreciation and amortization
|
$
|
2,120
|
|
|
$
|
940
|
|
|
$
|
82
|
|
|
$
|
3,142
|
|
|
Dividend income
|
$
|
413
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
413
|
|
|
Interest income
|
$
|
32
|
|
|
$
|
—
|
|
|
$
|
55
|
|
|
$
|
87
|
|
|
Interest expense, net
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
531
|
|
|
$
|
531
|
|
|
Income tax (benefit) expense
|
$
|
(609
|
)
|
|
$
|
1,763
|
|
|
$
|
(13,981
|
)
|
|
$
|
(12,827
|
)
|
|
|
|
|
|
|
|
|
|
||||||||
|
Nine Months Ended February 25, 2018
|
|
|
|
|
|
|
|
|
|||||||
|
Net sales
|
$
|
333,915
|
|
|
$
|
49,236
|
|
|
$
|
—
|
|
|
$
|
383,151
|
|
|
International sales
|
$
|
56,259
|
|
|
$
|
19,330
|
|
|
$
|
—
|
|
|
$
|
75,589
|
|
|
Gross profit
|
$
|
33,181
|
|
|
$
|
20,348
|
|
|
$
|
—
|
|
|
$
|
53,529
|
|
|
Net income from continuing operations
|
$
|
365
|
|
|
$
|
7,280
|
|
|
$
|
11,405
|
|
|
$
|
19,050
|
|
|
Depreciation and amortization
|
$
|
6,050
|
|
|
$
|
2,715
|
|
|
$
|
311
|
|
|
$
|
9,076
|
|
|
Dividend income
|
$
|
1,238
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,238
|
|
|
Interest income
|
$
|
60
|
|
|
$
|
—
|
|
|
$
|
100
|
|
|
$
|
160
|
|
|
Interest expense, net
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,415
|
|
|
$
|
1,415
|
|
|
Income tax (benefit) expense
|
$
|
393
|
|
|
$
|
2,110
|
|
|
$
|
(13,855
|
)
|
|
$
|
(11,352
|
)
|
|
(1)
|
During the third quarter of fiscal 2019, the Company started consolidating Yucatan Foods whose results are included in the Company's operating results starting from December 1, 2018. See Note 2 - Acquisition for more details of this transaction.
|
|
(2)
|
Beginning in first quarter of fiscal 2019, the Company began allocating interest expense to its reportable segments in information provided to its CODM to enhance visibility into how financing activities impact the discrete financial results.
|
|
|
February 24, 2019
|
|
May 27, 2018
|
||||
|
Current and other assets, discontinued operations:
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
—
|
|
|
$
|
(8
|
)
|
|
Accounts receivable
|
—
|
|
|
518
|
|
||
|
Inventory
|
—
|
|
|
—
|
|
||
|
Other assets
|
—
|
|
|
—
|
|
||
|
Total assets, discontinued operations
|
$
|
—
|
|
|
$
|
510
|
|
|
|
|
|
|
||||
|
Other current liabilities, discontinued operations:
|
|
|
|
||||
|
Accounts payable
|
$
|
—
|
|
|
$
|
230
|
|
|
Accrued expenses and other current liabilities
|
—
|
|
|
228
|
|
||
|
Total other current liabilities, discontinued operations
|
$
|
—
|
|
|
$
|
458
|
|
|
|
Three Months Ended February 25, 2018
|
|
Nine Months Ended
February 25, 2018 |
||||
|
Revenues
|
$
|
4,414
|
|
|
$
|
25,986
|
|
|
Cost of sales
|
(4,092
|
)
|
|
(24,349
|
)
|
||
|
Selling, general and administrative
|
(599
|
)
|
|
(1,976
|
)
|
||
|
Other
|
—
|
|
|
—
|
|
||
|
Loss from discontinued operations, before taxes
|
(277
|
)
|
|
(339
|
)
|
||
|
Income tax benefit
|
82
|
|
|
100
|
|
||
|
Loss from discontinued operations, net of tax
|
$
|
(195
|
)
|
|
$
|
(239
|
)
|
|
(1)
|
Establish strategic relationships with market leaders:
Lifecore will continue to develop applications for products with partners who have strong marketing, sales, and distribution capabilities to end-user markets. Through its strong reputation and history of providing pharmaceutical grade HA and products, Lifecore has been able to establish long-term relationships with the market leading ophthalmic surgical companies, and leverages those partnerships to attract new relationships in other medical markets.
|
|
(2)
|
Expand medical applications for HA:
Due to the growing knowledge of the unique characteristics of HA, and the role it plays in normal physiology, Lifecore continues to identify and pursue opportunities for the use of HA in other medical applications, such as wound care, aesthetic surgery, drug delivery, next generation orthopedics and device coatings and through sales to academic and corporate research customers. Further applications may involve expanding process development activity and/or additional licensing of technology.
|
|
(3)
|
Utilize manufacturing infrastructure to pursue contract aseptic filling
and fermentation opportunities:
Lifecore has made strategic capital investments in its CDMO business focusing on extending its aseptic filling capacity and capabilities. It is investing in this segment to meet increasing partner demand and attract new contract filling opportunities outside of HA markets. Lifecore is using its manufacturing capabilities to provide contract manufacturing and development services to its partners in the area of sterile pre-filled syringes and vials, as well as, fermentation and purification requirements.
|
|
(4)
|
Maintain flexibility in product development and supply relationships:
Lifecore’s vertically integrated development and manufacturing capabilities allow it to establish a variety of contractual relationships with global corporate partners. Lifecore’s role in these relationships extends from supplying HA raw materials to providing technology transfer and development services to manufacturing aseptically filled, finished sterile products, and assuming full supply chain responsibilities.
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||||||||
|
|
February 24, 2019
|
|
February 25, 2018
|
|
Change
|
|
February 24, 2019
|
|
February 25, 2018
|
|
Change
|
||||||||||
|
Curation Foods
|
$
|
131,984
|
|
|
$
|
121,950
|
|
|
8
|
%
|
|
$
|
353,502
|
|
|
$
|
333,915
|
|
|
6
|
%
|
|
Lifecore
|
23,703
|
|
|
22,959
|
|
|
3
|
%
|
|
51,765
|
|
|
49,236
|
|
|
5
|
%
|
||||
|
Total Revenues
|
$
|
155,687
|
|
|
$
|
144,909
|
|
|
7
|
%
|
|
$
|
405,267
|
|
|
$
|
383,151
|
|
|
6
|
%
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||||||||
|
|
February 24, 2019
|
|
February 25, 2018
|
|
Change
|
|
February 24, 2019
|
|
February 25, 2018
|
|
Change
|
||||||||||
|
Curation Foods
|
$
|
9,641
|
|
|
$
|
8,197
|
|
|
18
|
%
|
|
$
|
33,926
|
|
|
$
|
33,181
|
|
|
2
|
%
|
|
Lifecore
|
11,576
|
|
|
11,609
|
|
|
—
|
%
|
|
20,221
|
|
|
20,348
|
|
|
(1
|
%)
|
||||
|
Total Gross Profit
|
$
|
21,217
|
|
|
$
|
19,806
|
|
|
7
|
%
|
|
$
|
54,147
|
|
|
$
|
53,529
|
|
|
1
|
%
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||||||||
|
|
February 24, 2019
|
|
February 25, 2018
|
|
Change
|
|
February 24, 2019
|
|
February 25, 2018
|
|
Change
|
||||||||||
|
Curation Foods
|
$
|
1,301
|
|
|
$
|
1,439
|
|
|
(10
|
)%
|
|
$
|
3,833
|
|
|
$
|
3,944
|
|
|
(3
|
)%
|
|
Lifecore
|
1,271
|
|
|
1,406
|
|
|
(10
|
)%
|
|
3,701
|
|
|
4,108
|
|
|
(10
|
%)
|
||||
|
Other
|
169
|
|
|
268
|
|
|
(37
|
)%
|
|
573
|
|
|
1,152
|
|
|
(50
|
%)
|
||||
|
Total R&D
|
$
|
2,741
|
|
|
$
|
3,113
|
|
|
(12
|
)%
|
|
$
|
8,107
|
|
|
$
|
9,204
|
|
|
(12
|
%)
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||||||||
|
|
February 24, 2019
|
|
February 25, 2018
|
|
Change
|
|
February 24, 2019
|
|
February 25, 2018
|
|
Change
|
||||||||||
|
Curation Foods
|
$
|
14,072
|
|
|
$
|
8,343
|
|
|
69
|
%
|
|
$
|
32,687
|
|
|
$
|
25,039
|
|
|
31
|
%
|
|
Lifecore
|
1,638
|
|
|
1,444
|
|
|
13
|
%
|
|
4,883
|
|
|
4,387
|
|
|
11
|
%
|
||||
|
Other
|
133
|
|
|
3,421
|
|
|
(96
|
)%
|
|
6,890
|
|
|
9,384
|
|
|
(27
|
)%
|
||||
|
Total SG&A
|
$
|
15,843
|
|
|
$
|
13,208
|
|
|
20
|
%
|
|
$
|
44,460
|
|
|
$
|
38,810
|
|
|
15
|
%
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||||||||
|
|
February 24, 2019
|
|
February 25, 2018
|
|
Change
|
|
February 24, 2019
|
|
February 25, 2018
|
|
Change
|
||||||||||
|
Dividend Income
|
$
|
413
|
|
|
$
|
413
|
|
|
0
|
%
|
|
$
|
1,238
|
|
|
$
|
1,238
|
|
|
0
|
%
|
|
Interest Income
|
$
|
34
|
|
|
$
|
87
|
|
|
(61
|
)%
|
|
$
|
113
|
|
|
$
|
160
|
|
|
(29
|
)%
|
|
Interest Expense
|
$
|
(1,771
|
)
|
|
$
|
(531
|
)
|
|
234
|
%
|
|
$
|
(3,275
|
)
|
|
$
|
(1,415
|
)
|
|
131
|
%
|
|
Other Income
|
$
|
—
|
|
|
$
|
—
|
|
|
NM
|
|
|
$
|
1,600
|
|
|
$
|
2,200
|
|
|
(27
|
%)
|
|
Income Tax (Expense) Benefit
|
$
|
(242
|
)
|
|
$
|
12,827
|
|
|
NM
|
|
|
$
|
(584
|
)
|
|
$
|
11,352
|
|
|
NM
|
|
|
Exhibit
Number
|
Exhibit Title
|
|
CEO Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
CFO Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
CEO Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
CFO Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
101.INS**
|
XBRL Instance
|
|
|
|
|
101.SCH**
|
XBRL Taxonomy Extension Schema
|
|
|
|
|
101.CAL**
|
XBRL Taxonomy Extension Calculation
|
|
|
|
|
101.DEF**
|
XBRL Taxonomy Extension Definition
|
|
|
|
|
101.LAB**
|
XBRL Taxonomy Extension Labels
|
|
|
|
|
101.PRE**
|
XBRL Taxonomy Extension Presentation
|
|
|
|
|
+
|
Filed herewith.
|
|
|
|
|
** XBRL
|
information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.
|
|
|
LANDEC CORPORATION
|
||
|
|
|
|
|
|
|
By:
|
/s/
|
Gregory S. Skinner
|
|
|
|
Gregory S. Skinner
|
|
|
|
|
Vice President of Finance and Administration and Chief Financial Officer
|
|
|
|
|
(Principal Financial and Accounting Officer)
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|